Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia

O. Wiklund, S. O. Olofsson, G. Fager, G. Bondjers, B. Angelin, M. Erikson, Lars Berglund

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2·5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n=48) than in those without (n=72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30%, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.

Original languageEnglish (US)
Pages (from-to)1360-1363
Number of pages4
JournalThe Lancet
Volume335
Issue number8702
DOIs
StatePublished - Jun 9 1990
Externally publishedYes

Fingerprint

Apoprotein(a)
Hyperlipoproteinemia Type II
Myocardial Ischemia
Cholestyramine Resin
Pravastatin
Serum
LDL Cholesterol
Coronary Disease
Multivariate Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wiklund, O., Olofsson, S. O., Fager, G., Bondjers, G., Angelin, B., Erikson, M., & Berglund, L. (1990). Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. The Lancet, 335(8702), 1360-1363. https://doi.org/10.1016/0140-6736(90)91242-3

Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. / Wiklund, O.; Olofsson, S. O.; Fager, G.; Bondjers, G.; Angelin, B.; Erikson, M.; Berglund, Lars.

In: The Lancet, Vol. 335, No. 8702, 09.06.1990, p. 1360-1363.

Research output: Contribution to journalArticle

Wiklund, O, Olofsson, SO, Fager, G, Bondjers, G, Angelin, B, Erikson, M & Berglund, L 1990, 'Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia', The Lancet, vol. 335, no. 8702, pp. 1360-1363. https://doi.org/10.1016/0140-6736(90)91242-3
Wiklund O, Olofsson SO, Fager G, Bondjers G, Angelin B, Erikson M et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. The Lancet. 1990 Jun 9;335(8702):1360-1363. https://doi.org/10.1016/0140-6736(90)91242-3
Wiklund, O. ; Olofsson, S. O. ; Fager, G. ; Bondjers, G. ; Angelin, B. ; Erikson, M. ; Berglund, Lars. / Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. In: The Lancet. 1990 ; Vol. 335, No. 8702. pp. 1360-1363.
@article{0d4da5160ad04d69ae492313f82d5bca,
title = "Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia",
abstract = "Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2·5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n=48) than in those without (n=72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30{\%}, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.",
author = "O. Wiklund and Olofsson, {S. O.} and G. Fager and G. Bondjers and B. Angelin and M. Erikson and Lars Berglund",
year = "1990",
month = "6",
day = "9",
doi = "10.1016/0140-6736(90)91242-3",
language = "English (US)",
volume = "335",
pages = "1360--1363",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8702",

}

TY - JOUR

T1 - Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia

AU - Wiklund, O.

AU - Olofsson, S. O.

AU - Fager, G.

AU - Bondjers, G.

AU - Angelin, B.

AU - Erikson, M.

AU - Berglund, Lars

PY - 1990/6/9

Y1 - 1990/6/9

N2 - Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2·5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n=48) than in those without (n=72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30%, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.

AB - Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2·5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n=48) than in those without (n=72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30%, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.

UR - http://www.scopus.com/inward/record.url?scp=0025358421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025358421&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(90)91242-3

DO - 10.1016/0140-6736(90)91242-3

M3 - Article

C2 - 1971660

AN - SCOPUS:0025358421

VL - 335

SP - 1360

EP - 1363

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8702

ER -